What is the management plan for a patient with an elevated Keppra (levetiracetam) level?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Elevated Levetiracetam Levels

For patients with elevated levetiracetam levels, supportive care is the mainstay of treatment, including monitoring vital signs, airway protection if needed, and consideration of hemodialysis in severe cases or patients with renal impairment. 1

Initial Assessment and Stabilization

  • Assess airway, breathing, and circulation; provide respiratory support if the patient shows signs of respiratory depression 2
  • Monitor vital signs and observe the patient's clinical status closely 1
  • Check blood glucose to rule out hypoglycemia as a contributing factor 2
  • Perform neurological assessment, particularly level of consciousness and deep tendon reflexes, as diminished reflexes may be observed with levetiracetam toxicity 3

Immediate Management

  • If the overdose is recent (within 1-2 hours), consider gastric decontamination via emesis or gastric lavage while maintaining airway protection 1
  • Contact a Certified Poison Control Center for up-to-date management recommendations 1
  • Provide general supportive care as there is no specific antidote for levetiracetam overdose 1

Specific Interventions

  • For severe toxicity with significantly elevated levels, consider hemodialysis which can clear approximately 50% of levetiracetam in 4 hours 1
  • Hemodialysis is particularly indicated in patients with:
    • Significant renal impairment
    • Severe clinical manifestations (coma, significant respiratory depression)
    • Extremely high serum concentrations 1

Management of Complications

  • If seizures occur during the recovery period, administer lorazepam 0.05-0.1 mg/kg IV (maximum 1-2 mg) 2
  • For respiratory depression requiring intubation, provide appropriate ventilatory support until the medication clears 3
  • Monitor for and treat somnolence, agitation, aggression, and depressed level of consciousness, which are common manifestations of levetiracetam overdose 1

Monitoring and Follow-up

  • Obtain serial levetiracetam serum concentrations to track elimination (therapeutic range is 10-37 μg/mL) 3
  • The elimination half-life of levetiracetam is approximately 5-7 hours in patients with normal renal function, even at concentrations 10-40 times higher than therapeutic levels 3
  • Monitor for seizure recurrence during the period of medication adjustment 2

Resumption of Therapy

  • Once levels have normalized and symptoms have resolved, consider resuming levetiracetam at a reduced dose with careful monitoring 2
  • When restarting therapy, consider using doses between 1000-3000 mg/day for adults, with adjustments based on renal function and clinical response 4
  • Do not abruptly discontinue long-term levetiracetam therapy as this could precipitate withdrawal seizures 2

Common Pitfalls and Caveats

  • Avoid administering medications that cause CNS depression which could worsen symptoms 2
  • Be aware that generic substitutions of levetiracetam may result in different serum levels and potentially breakthrough seizures in some patients 5
  • Recognize that behavioral side effects (agitation, hostility, anxiety) may occur with levetiracetam therapy and can be mistaken for other conditions 6

References

Guideline

Management of Elevated Levetiracetam Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.

Journal of toxicology. Clinical toxicology, 2002

Guideline

Levetiracetam Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Catatonia induced by levetiracetam.

Epilepsy & behavior : E&B, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.